行情

FATE

FATE

Fate
NASDAQ

实时行情|Nasdaq Last Sale

25.65
+1.36
+5.58%
盘后: 25.96 +0.31 +1.21% 16:31 01/17 EST
开盘
24.68
昨收
24.30
最高
25.83
最低
24.31
成交量
134.44万
成交额
--
52周最高
25.83
52周最低
12.59
市值
19.39亿
市盈率(TTM)
-19.5846
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FATE 新闻

  • 波音盼中美经贸协议带来订单 美媒:已落后空客几个月
  • 环球网.2小时前
  • 投行:"弹簧效应"正在积聚 镑美很快迎来"爆炸性"走势
  • FX168.3小时前
  • 特朗普的下任美联储主席会是一位“金甲虫”吗?
  • 新浪美股.3小时前
  • 中缅经济走廊开启实质规划建设
  • 新浪财经综合.5小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

FATE 简况

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
展开

Webull提供Fate Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。